Omeprazole Inhibits Glioblastoma Cell Invasion and Tumor Growth

dc.contributor.authorJin, Un-Hoen
dc.contributor.authorMichelhaugh, Sharon K.en
dc.contributor.authorPolin, Lisa A.en
dc.contributor.authorShrestha, Rupeshen
dc.contributor.authorMittal, Sandeepen
dc.contributor.authorSafe, Stephenen
dc.contributor.departmentFralin Biomedical Research Instituteen
dc.contributor.departmentVirginia Tech Carilion School of Medicineen
dc.date.accessioned2020-08-21T15:04:13Zen
dc.date.available2020-08-21T15:04:13Zen
dc.date.issued2020-07-28en
dc.date.updated2020-08-21T13:49:29Zen
dc.description.abstract<i>Background</i>: The aryl hydrocarbon receptor (AhR) is expressed in gliomas and the highest staining is observed in glioblastomas. A recent study showed that the AhR exhibited tumor suppressor-like activity in established and patient-derived glioblastoma cells and genomic analysis showed that this was due, in part, to suppression of CXCL12, CXCR4 and MMP9. <i>Methods</i>: Selective AhR modulators (SAhRMs) including AhR-active pharmaceuticals were screened for their inhibition of invasion using a spheroid invasion assay in patient-derived AhR-expressing 15-037 glioblastoma cells and in AhR-silenced 15-037 cells. Invasion, migration and cell proliferation were determined using spheroid invasion, Boyden chambers and scratch assay, and XTT metabolic assays for cell growth. Changes in gene and gene product expression were determined by real-time PCR and Western blot assays, respectively. In vivo antitumorigenic activity of omeprazole was determined in SCID mice bearing subcutaneous patient-derived 15-037 cells. <i>Results</i>: Results of a screening assay using patient-derived 15-037 cells (wild-type and AhR knockout) identified the AhR-active proton pump inhibitor omeprazole as an inhibitor of glioblastoma cell invasion and migration only AhR-expressing cells but not in cells where the AhR was downregulated. Omeprazole also enhanced AhR-dependent repression of the pro-invasion CXCL12, CXCR4 and MMP9 genes, and interactions and effectiveness of omeprazole plus temozolomide were response-dependent. Omeprazole (100 mg/kg/injection) inhibited and delayed tumors in SCID mice bearing patient-derived 15-037 cells injected subcutaneously. <i>Conclusion</i>: Our results demonstrate that omeprazole enhances AhR-dependent inhibition of glioblastoma invasion and highlights a potential new avenue for development of a novel therapeutic mechanism-based approach for treating glioblastoma.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationJin, U.-H.; Michelhaugh, S.K.; Polin, L.A.; Shrestha, R.; Mittal, S.; Safe, S. Omeprazole Inhibits Glioblastoma Cell Invasion and Tumor Growth. Cancers 2020, 12, 2097.en
dc.identifier.doihttps://doi.org/10.3390/cancers12082097en
dc.identifier.urihttp://hdl.handle.net/10919/99818en
dc.language.isoenen
dc.publisherMDPIen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectpatient-derived xenograften
dc.subjectglioblastomaen
dc.subjectselective AhR modulatorsen
dc.subjectgrowth inhibitionen
dc.subjectcell invasionen
dc.titleOmeprazole Inhibits Glioblastoma Cell Invasion and Tumor Growthen
dc.title.serialCancersen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.dcmitypeStillImageen

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
cancers-12-02097.pdf
Size:
3.95 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description: